Study summary

Weekly semaglutide cut heavy drinking days more than therapy alone

Semaglutide in AUD with obesity (Copenhagen trial) · 108 people, randomized trial · Published May 2026, The Lancet

41.1percentage-point drop in heavy drinking days, vs 26.4 with placebo

What was tested

Weekly semaglutide 2.4 mg or placebo for 26 weeks, both with cognitive behavioural therapy, in treatment-seeking adults with moderate to severe alcohol use disorder and obesity.

What they found

What it means

The strongest evidence yet that GLP-1 drugs reduce drinking; larger trials are under way.

Lancet, via PubMed ↗ Trial record NCT05895643 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.